Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising/recruitment
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Recently published
    • Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Recently published
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising/recruitment
  • Contact
Vasopressin mediates fructose-induced metabolic syndrome by activating the V1b receptor
Ana Andres-Hernando, … , Richard J. Johnson, Miguel A. Lanaspa
Ana Andres-Hernando, … , Richard J. Johnson, Miguel A. Lanaspa
Published December 15, 2020
Citation Information: JCI Insight. 2021;6(1):e140848. https://doi.org/10.1172/jci.insight.140848.
View: Text | PDF
Research Article Endocrinology Metabolism

Vasopressin mediates fructose-induced metabolic syndrome by activating the V1b receptor

  • Text
  • PDF
Abstract

Subjects with obesity frequently have elevated serum vasopressin levels, noted by measuring the stable analog, copeptin. Vasopressin acts primarily to reabsorb water via urinary concentration. However, fat is also a source of metabolic water, raising the possibility that vasopressin might have a role in fat accumulation. Fructose has also been reported to stimulate vasopressin. Here, we tested the hypothesis that fructose-induced metabolic syndrome is mediated by vasopressin. Orally administered fructose, glucose, or high-fructose corn syrup increased vasopressin (copeptin) concentrations and was mediated by fructokinase, an enzyme specific for fructose metabolism. Suppressing vasopressin with hydration both prevented and ameliorated fructose-induced metabolic syndrome. The vasopressin effects were mediated by the vasopressin 1b receptor (V1bR), as V1bR-KO mice were completely protected, whereas V1a-KO mice paradoxically showed worse metabolic syndrome. The mechanism is likely mediated in part by de novo expression of V1bR in the liver that amplifies fructokinase expression in response to fructose. Thus, our studies document a role for vasopressin in water conservation via the accumulation of fat as a source of metabolic water. Clinically, they also suggest that increased water intake may be a beneficial way to both prevent or treat metabolic syndrome.

Authors

Ana Andres-Hernando, Thomas J. Jensen, Masanari Kuwabara, David J. Orlicky, Christina Cicerchi, Nanxing Li, Carlos A. Roncal-Jimenez, Gabriela E. Garcia, Takuji Ishimoto, Paul S. Maclean, Petter Bjornstad, Laura Gabriela Sanchez-Lozada, Mehmet Kanbay, Takahiko Nakagawa, Richard J. Johnson, Miguel A. Lanaspa

×

Figure 2

Fructose metabolism via fructokinase is necessary for vasopressin production and secretion.

Options: View larger image (or click on image) Download as PowerPoint
Fructose metabolism via fructokinase is necessary for vasopressin produc...
(A) Hypothalamic mRNA levels of fructokinase (KHK) in mice receiving water or a 10% fructose solution for 30 weeks. (B) Cumulative total and fructose-derived caloric intake in WT (black), KHK-A–KO (orange), and KHK-A/C–KO (blue) mice receiving equal amounts of fructose for 30 weeks. (C) Hypothalamic mRNA levels of vasopressin in WT, KHK-A–KO, and KHK-A/C–KO mice receiving equal amounts of fructose for 30 weeks. (D) Vasopressin levels in pituitary of WT, KHK-A–KO, and KHK-A/C–KO mice receiving equal amounts of fructose for 30 weeks. (E) Serum copeptin levels in WT, KHK-A–KO, and KHK-A/C–KO mice receiving equal amounts of fructose for 30 weeks. (F) Representative Western blot (n = 3 total blots) for KHK and actin in liver, gut, and kidney tissues from WT (black), KHK-A/C–KO (blue), and liver-specific KHK-A/C–KO mice (KHKFl/FlXCreAlb, green). (G) Serum copeptin levels in WT, KHK-A/C–KO, and liver-specific KHK-A/C–KO mice receiving equal amounts of fructose for 30 weeks. (H) Serum copeptin levels in WT and KHK-A/C–KO mice receiving glucose (10%) or HFCS (10%) solutions for 30 weeks. The data in A–E and G and H are presented as the mean ± SD and analyzed by 1-way ANOVA with Tukey’s post hoc analysis. *P < 0.05, **P < 0.01. n = 6 mice per group. See also Supplemental Table 1 and Supplemental Table 2. KHK, ketohexokinase; KHK-A, A isoform of KHK; KHK-A/C, both A and C isoforms of KHK; HFCS, high-fructose corn syrup.
Follow JCI Insight:
Copyright © 2021 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts